Use of the ODD-luciferase transgene for the non-invasive imaging of spontaneous tumors in mice

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Goldman, Scott J ^a,d   Chen, Elizabeth ^a,d   Taylor, Robert ^a,d   Zhang, Sheng ^c   Petrosky, Whitney ^b,d   Reiss, Michael ^b,d   Jin, Shengkan ^b,d  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUCIFERASE; LUCIFERIN; OXYGEN DEPENDENT DEGRADATION DOMAIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BREAST CARCINOMA; CONTROLLED STUDY; HISTOPATHOLOGY; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; OXYGEN DEPENDENT DEGRADATION LUCIFERASE TRANSGENE; SIGNAL TRANSDUCTION; SPECTRUM; TRANSGENE; TUMOR VOLUME; ANIMAL; CELL HYPOXIA; CHEMISTRY; DIAGNOSTIC IMAGING; EXPERIMENTAL NEOPLASM; FEMALE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; METHODOLOGY; MOUSE MAMMARY TUMOR ONCOVIRUS; PATHOLOGY; PRECANCER; PROTEIN TERTIARY STRUCTURE; REMISSION; TRANSGENIC MOUSE;

ANIMALIA; MOUSE MAMMARY TUMOR VIRUS; MUS; MUS MUSCULUS;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL HYPOXIA; DIAGNOSTIC IMAGING; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUCIFERASES; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; PRECANCEROUS CONDITIONS; PROTEIN STRUCTURE, TERTIARY; REMISSION INDUCTION; TRANSGENES; TUMOR BURDEN;

EID: 79953190404     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018269     Document Type: Article

References (26)

1. Weissleder R, Pittet MJ, (2008) Imaging in the era of molecular oncology. Nature 452: 580-589.
2. Kyriazi S, Kaye SB, deSouza NM., Imaging ovarian cancer and peritoneal metastases-current and emerging techniques. Nat Rev Clin Oncol 7: 381-393.
3. Oyen WJ, van der Graaf WT, (2009) Molecular imaging of solid tumors: exploiting the potential. Nat Rev Clin Oncol 6: 609-611.
4. Waldman AD, Jackson A, Price SJ, Clark CA, Booth TC, et al. (2009) Quantitative imaging biomarkers in neuro-oncology. Nat Rev Clin Oncol 6: 445-454.
5. Dennis C, (2006) Cancer: off by a whisker. Nature 442: 739-741.
6. Frese KK, Tuveson DA, (2007) Maximizing mouse cancer models. Nat Rev Cancer 7: 645-658.
7. Sharpless NE, Depinho RA, (2006) The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5: 741-754.
8. Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, et al. (2007) Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 12: 160-170.
9. Schetter AJ, Heegaard NH, Harris CC., Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 31: 37-49.
10. Tuveson DA, Jacks T, (2002) Technologically advanced cancer modeling in mice. Curr Opin Genet Dev 12: 105-110.
11. Jonkers J, Berns A, (2002) Conditional mouse models of sporadic cancer. Nat Rev Cancer 2: 251-265.
12. Gross S, Piwnica-Worms D, (2005) Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 7: 5-15.
13. Tennant DA, Duran RV, Gottlieb E., Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267-277.
14. Kaelin WG Jr, (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873.
15. Harris AL, (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47.
16. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
17. Safran M, Kim WY, O'Connell F, Flippin L, Gunzler V, et al. (2006) Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A 103: 105-110.
18. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P, (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54: 105-115.
19. Yue Z, Jin S, Yang C, Levine AJ, Heintz N, (2003) Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A 100: 15077-15082.
20. Muller WJ, (1991) Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer. Cancer Metastasis Rev 10: 217-227.
21. Muller WJ, Arteaga CL, Muthuswamy SK, Siegel PM, Webster MA, et al. (1996) Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol 16: 5726-5736.
22. Stern DF, (2008) ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 13: 215-223.
23. Albanell J, Baselga J, (1999) The ErbB receptors as targets for breast cancer therapy. J Mammary Gland Biol Neoplasia 4: 337-351.
24. Dewhirst MW, (2009) Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 172: 653-665.
25. Dewhirst MW, Cao Y, Moeller B, (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8: 425-437.
26. Kim JB, Urban K, Cochran E, Lee S, Ang A, et al. Non-invasive detection of a small number of bioluminescent cancer cells in vivo. PLoS One 5: e9364.